VIA EDGAR
June 21, 2021
U.S. Securities and Exchange Commission
Division of Corporation Finance
Mail Stop 4561
100 F Street, N.E.
Washington, D.C. 20549
| Attn: | Kasey Robinson |
Jeffrey Gabor |
| Re: | Monte Rosa Therapeutics, Inc. |
Acceleration Request for Registration Statement on Form S-1 |
File No. 333-256773 |
Requested Date: June 23, 2021 |
Requested Time: 4:00 p.m. Eastern Standard Time |
Dear Ms. Robinson and Mr. Gabor:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Monte Rosa Therapeutics, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to June 23, 2021, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling Marishka DeToy at (617) 570-1926. We also respectfully request that a copy of the written order from the Securities and Exchange Commission (the “Commission”) verifying the effective time and date of the Registration Statement be sent to our counsel, Goodwin Procter LLP, Attention: Marishka DeToy, by facsimile to (617) 321-4360 or by email at mdetoy@goodwinlaw.com.
[Remainder of page left intentionally blank]
If you have any questions regarding this request, please contact Marishka DeToy of Goodwin Procter LLP at (617) 570-1926.
| Sincerely, |
| MONTE ROSA THERAPEUTICS, INC. |
| /s/ Markus Warmuth |
Markus Warmuth President and Chief Executive Officer |
| cc: | Ajim Tamboli, Monte Rosa Therapeutics, Inc. |
Robert E. Puopolo, Goodwin Procter LLP |
Marishka DeToy, Goodwin Procter LLP |
